Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000323235 | SCV000331597 | pathogenic | not provided | 2017-04-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000809801 | SCV000949977 | pathogenic | Qualitative or quantitative defects of dysferlin | 2024-01-22 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln1278*) in the DYSF gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). This variant is present in population databases (rs727503911, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with distal myopathy (PMID: 16010686, 17698709, 25135358). ClinVar contains an entry for this variant (Variation ID: 167025). For these reasons, this variant has been classified as Pathogenic. |
Johns Hopkins Genomics, |
RCV000984259 | SCV001430649 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-06-16 | criteria provided, single submitter | clinical testing | This DYSF variant (rs727503911) is rare (<0.1%) in a large population dataset4 (gnomAD: 4/279112 total alleles; 0.0014%; no homozygotes) and has an entry in ClinVar. This variant has been reported previously in a homozygous or compound heterozygous state in individuals affected with LGMDR2 or MMD1. This nonsense variant results in a premature stop codon in exon 34 of 56 likely leading to nonsense?mediated decay and lack of protein production. We consider this variant to be pathogenic. |
Revvity Omics, |
RCV000323235 | SCV002021862 | pathogenic | not provided | 2021-05-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002492572 | SCV002781083 | pathogenic | Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Distal myopathy with anterior tibial onset | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000323235 | SCV004154967 | pathogenic | not provided | 2023-04-01 | criteria provided, single submitter | clinical testing | DYSF: PVS1, PM2, PM3 |
Baylor Genetics | RCV003467211 | SCV004194175 | pathogenic | Miyoshi muscular dystrophy 1 | 2024-03-13 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV000984259 | SCV005373711 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2023-05-20 | criteria provided, single submitter | clinical testing | The observed stop gained c.3886C>T(p.Gln1296Ter) variant in DYSF gene has been reported previously in homozygous or compound heterozygous state in individual(s) affected with limb-girdle muscular dystrophies (LGMD2) (Stehlíková et al., 2014; Rufibach et al., 2023). This variant is reported with the allele frequency of 0.001% in the gnomAD Exomes. This variant has been reported to the ClinVar database as Pathogenic (multiple submitters). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (Nguyen et al., 2007). Computational evidence (MutationTaster - Disease causing automatic) predicts damaging effect on protein structure and function for this variant. For these reasons, this variant has been classified as Pathogenic. |
Counsyl | RCV000984259 | SCV001132383 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2016-11-18 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000984259 | SCV001462798 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-09-16 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003917498 | SCV004736704 | pathogenic | DYSF-related disorder | 2023-11-14 | no assertion criteria provided | clinical testing | The DYSF c.3832C>T variant is predicted to result in premature protein termination (p.Gln1278*). This variant was reported in individuals with DYSF-related muscular dystrophy (Nguyen et al 2005. PubMed ID: 16010686; Klinge et al 2009. PubMed ID: 19528035; Moore et al 2021. PubMed ID: 33610434; Stehlíková et al 2014. PubMed ID: 25135358). This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-71827961-C-T). Nonsense variants in DYSF are expected to be pathogenic. This variant is interpreted as pathogenic. |